Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Bicara Therapeutics Inc. Common Stock (BCAX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/27/2025: BCAX (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
Analysts rated it
Well-followed company, solid analyst reports, reliable data for confident investing.
1 Year Target Price $
1 Year Target Price $
| 4 | Strong Buy |
| 2 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -48.68% | Avg. Invested days 13 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/27/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 900.58M USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta - | 52 Weeks Range 7.80 - 28.09 | Updated Date 06/14/2025 |
52 Weeks Range 7.80 - 28.09 | Updated Date 06/14/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -3.75 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) - | Return on Equity (TTM) - |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 381353806 | Price to Sales(TTM) - |
Enterprise Value 381353806 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding 54385900 | Shares Floating 29577855 |
Shares Outstanding 54385900 | Shares Floating 29577855 | ||
Percent Insiders 0.42 | Percent Institutions - |
Analyst Ratings
Rating 4.43 | Target Price - | Buy 2 | Strong Buy 4 |
Buy 2 | Strong Buy 4 | ||
Hold 1 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Bicara Therapeutics Inc. Common Stock
Company Overview
History and Background
Bicara Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing dual-action biologics to elicit a potent and durable anti-tumor response. Founded in 2017, it has focused on advancing bifunctional antibodies to target both tumors and immune cells.
Core Business Areas
- Bifunctional Antibody Development: Develops therapeutics that combine tumor targeting with immune cell activation to treat cancer.
Leadership and Structure
The leadership team consists of experienced professionals in biotechnology and drug development. The company has a typical structure for a clinical-stage biotech, with departments focused on research, development, clinical trials, and corporate operations.
Top Products and Market Share
Key Offerings
- BCA101: BCA101 is a lead asset targeting EGFR and TGFu03b2. It is being developed for advanced solid tumors. Market share information is not publicly available for a product still in clinical development. Competitors would include companies developing EGFR inhibitors and TGFu03b2 inhibitors such as Eli Lilly (LYLY) and Bristol Myers Squibb (BMY).
Market Dynamics
Industry Overview
The oncology therapeutics market is large and competitive, with increasing focus on immunotherapies and targeted therapies. Biotech companies are actively developing novel agents to address unmet needs in cancer treatment.
Positioning
Bicara Therapeutics is positioned within the oncology market with its dual-action biologics, aiming to provide improved efficacy and durability compared to existing therapies. Its competitive advantage lies in its bifunctional antibody platform and the potential for novel combination therapies.
Total Addressable Market (TAM)
The total addressable market for cancer therapies is estimated to be in the hundreds of billions of dollars. Bicara's success depends on its ability to gain approval for its lead asset.
Upturn SWOT Analysis
Strengths
- Novel bifunctional antibody platform
- Experienced management team
- Potential for improved efficacy and durability compared to existing therapies
Weaknesses
- Early-stage clinical development
- High cash burn rate
- Dependence on clinical trial success
Opportunities
- Partnerships with larger pharmaceutical companies
- Expansion of pipeline into new cancer targets
- Positive clinical trial results leading to regulatory approval
Threats
- Clinical trial failures
- Competition from other immunotherapy and targeted therapy developers
- Regulatory hurdles and delays
Competitors and Market Share
Key Competitors
- LYLY
- BMY
- MRTX
Competitive Landscape
Bicara Therapeutics competes with larger pharmaceutical companies developing cancer therapies. Its competitive advantage lies in its differentiated approach with dual-action biologics.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is limited given the company's recent founding. The focus is on advancing its pipeline.
Future Projections: Future growth depends on successful clinical trial outcomes and potential partnerships. Analyst estimates depend on market conditions.
Recent Initiatives: Recent initiatives include advancing BCA101 through clinical trials and expanding its research efforts into new targets.
Summary
Bicara Therapeutics is a clinical-stage biotech company with a novel dual-action biologic platform. Its success hinges on the clinical trials of its lead asset, BCA101. While the company has innovative technology and an experienced team, it faces risks associated with early-stage drug development and competition from established players. Cash burn rate is something the company needs to keep in mind and the company needs to obtain positive results to maintain its stock value.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company filings
- Analyst reports
- Industry publications
Disclaimers:
The analysis provided is for informational purposes only and should not be considered financial advice. Investment decisions should be based on individual risk tolerance and due diligence.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Bicara Therapeutics Inc. Common Stock
Exchange NASDAQ | Headquaters Boston, MA, United States | ||
IPO Launch date 2024-09-13 | CEO & Director Dr. Claire Mazumdar Clemon M.B.A., Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 55 | Website https://www.bicara.com |
Full time employees 55 | Website https://www.bicara.com | ||
Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the development of bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines a clinically validated epidermal growth factor receptor directed monoclonal antibody with a domain that binds to human transforming growth factor beta for the treatment of solid tumors. The company was incorporated in 2018 and is based in Boston, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.